Online inquiry

IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6658MR)

This product GTTS-WQ6658MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets ITGAV gene. The antibody can be applied in Ovarian Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001144999.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3685
UniProt ID P06756
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ITGAV, DI-17E6(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ6658MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ9658MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ4443MR IVTScrip™ mRNA-Anti-CTLA4, BMS-734016(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-734016
GTTS-WQ14989MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ811MR IVTScrip™ mRNA-Anti-LRRC15, ABBV-085(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABBV-085
GTTS-WQ7435MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ12219MR IVTScrip™ mRNA-Anti-TNFRSF4, MOXR-0916(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA MOXR-0916
GTTS-WQ15953MR IVTScrip™ mRNA-Anti-NGF, ZTS-00508841(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00508841
GTTS-WQ3934MR IVTScrip™ mRNA-Anti-CTLA4, BCD-145(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BCD-145
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW